Most Recent
A judge has suggested there may be merit in waiting for Johnson & Johnson to file a defence before deciding an application for a group costs order in a class action accusing the company of selling defective, carcinogenic talcum powder.
Former West Coast Eagles player Daniel Venables' case against two doctors and a neurologist has been struck out, with a judge finding he had failed to adequately plead a negligence case.
A class action against Allergan over recalled breast implants has lost its bid to strike out the US drug company’s defence that there was no known causal link between its implants and a certain form of cancer at the time of supply.
Norton Rose Fulbright has hired the former co-head of Baker McKenzie's Australian healthcare and life sciences group to join its corporate practice group in Sydney.
A judge has granted Johnson & Johnson's bid for soft class closure in a class action over alleged ineffective cold medications, saying it would aid in settlement negotiations.
Construction PRO
A judge has tossed a nuisance claim by the Perth Day Hospital against its neighbour Fitness Cartel, finding its use of the property for "hypersensitive" surgery and medical procedures was not an 'ordinary use' protected by nuisance law.
"Quite unsatisfactory", is how a judge has described a revived intellectual property dispute between German drug maker Merck KGaA and US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia.
Construction PRO
Lendlease has been tapped by Queensland as preferred contractor for the Redcliffe Hospital expansion project in Moreton Bay, a key part of the government's hospital rescue plan.
Johnson & Johnson has agreed to pay $7.9 billion to resolve multi-district litigation in the US alleging its talcum powder caused cancer, a settlement Shine Lawyers said was a positive development as it readies for a first case management hearing in its class action.
Lender RND Funding wants to revise its case against BDO Advisory and auditor Ernst & Young over advice given to defunct Adelaide company Gen1 Biotechnology, a week out from trial.